hims compounded semaglutide review & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky Shares of Hims & Hers

2000;279(3):E501-E507

Last week, the ABC revealed that doctors were warning people not to take drugs labelled as "retatrutide" after seeing multiple cases of life-threatening illness, including acute liver failure

Histological examination showed perivascular superficial and dermal chronic inflammatory cell infiltration associated with eosinophils and minimal spongiotic changes, and a direct immunofluorescence test was negative

Numerous lawsuits are now being filed against the manufacturer of Ozempic and Wegovy, Novo Nordisk, and Eli Lilly, which produces the GLP 1 medication Mounjaro

doi:10.1016/S0140-6736(23)01053-X PubMed: This trial evaluated retatrutide in 281 participants with type 2 diabetes, showing up to 16.94% weight loss and significant HbA1c reductions with favorable safety profile comparable to other GLP-1 based therapies